Positron Emission Tomography (PET) Articles

Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity.

Differentiation of true tumor progression from treatment-related effects remains a major unmet need in caring for patients with glioblastoma. Here, we report how the intraoperative combination of MRI with18F-fluciclovine PET guided surgical sampling in 2 patients with recurrent glioblastoma.

The primary aim of this retrospective, single-centre analysis was to assess the performance of 68Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA failure after radical prostatectomy (RP).

BERKELEY, CA (UroToday.com) - Molecular imaging by means of positron emission tomography (PET) provides a method to study metabolic activity of tumors in vivo.

Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PCa) cells and several PSMA ligands for PET imaging (PSMA-PET) are now available worldwide. 68Ga-PSMA-11 has already received American Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval, and PSMA-PET is currently suggested by several international guidelines to investigate PCa in different clinical settings.

BERKELEY, CA (UroToday.com) - Radical prostatectomy and radiation therapy are curative treatment options with equivalent outcomes as determined by biochemical recurrence-free survival.

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades.

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate disease. Radiomics signature (RS) is widely used for the analysis of overall survival (OS) in cancer diseases.

Introduction: The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with PSA persistence following salvage lymph node dissection (SLND) and pre/post procedure prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET).

Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa.

Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) found on T and pro-B cells. Pembrolizumab prevents PD-1 ligation by both PD-L1 and PD-L2, preventing the immune dysregulation that otherwise occurs when T-cells encounter cells expressing these ligands.

Low detection rate of conventional imaging and unspecific fluctuations of PSA can hamper early diagnosis of castration-resistant prostate cancer (CRPC). We thus assessed the value of PSMA-PET/CT in the detection of early CRPC (PSA ≤3 ng/mL).

BERKELEY, CA (UroToday.com) - Prostate cancer is one of the leading causes of the deaths of males in the United States.

Prostate-specific membrane antigen (PSMA) is an important biomarker expressed in the majority of prostate cancers. The favorable positron emission tomography (PET) imaging profile of the PSMA imaging agent 2-(3-(1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentane-dioic acid [(18)F]DCFPyL in preclinical prostate cancer models and in prostate cancer patients stimulated the development and validation of other fluorine-containing PSMA inhibitors to further enhance pharmacokinetics and simplify production methods.